Achieving critical FDA Phase 3 milestones represents the ultimate regulatory hurdle. Specifically, these milestones validate psychedelic-assisted psychotherapies as prescribable medicines.
Unlike organic fungi, which rely on a dense, indigestible chitin cell wall matrix that triggers acute localized inflammation in the
The ‘Direct Answer’ Lead A pivotal regulatory milestone triggers the 2026 Iboga ‘Addiction Reset’. Specifically, the April 18, 2026, Executive
Introduction: What Is a Therapeutic Psychedelic Experience? A Therapeutic Psychedelic Experience refers to the purposeful and guided use of psychedelic
